Johnson & Johnson Innovation - JJDC

Chris Picariello has led JJDC as president since 2019. He arrived from inside Johnson & Johnson, where he served as chief business officer and chief financial officer for the Innovative Medicine research and development unit, a background that keeps the venture arm tethered to the therapeutic priorities of the operating company rather than running as a standalone financial investor. Debi Watson serves as vice president of venture investments and is the unit's most public voice on strategy and on the discipline that has carried it through five decades of shifting healthcare cycles. The team sits within Johnson & Johnson Innovation, which pairs JJDC's equity investing with the JLABS incubator network and regional innovation centers, giving portfolio management teams access to Johnson & Johnson scientists, clinical expertise and commercial infrastructure alongside the capital itself.

JJDC raises no outside limited partner capital and has no numbered funds. Incorporated in 1973 as the venture investment arm of Johnson & Johnson, it invests directly off the parent company's balance sheet, which makes its capital evergreen and its holding periods open-ended. Johnson & Johnson had been taking minority positions in outside entrepreneurs since the 1960s; the 1973 incorporation formalized the practice and gave JJDC an unbroken record that reached the half-century mark in 2023, making it one of the oldest continuously operating corporate venture units anywhere. Deployment runs across pharmaceuticals, medical devices, consumer health and medtech, typically at Series A and later, and is coordinated with the wider Johnson & Johnson Innovation organization. Because commitments come from the corporate treasury rather than a fixed vintage, annual pace tracks Johnson & Johnson's own research, development and licensing priorities rather than a fund's investment period, and the unit carries no pressure to return capital on a ten-year clock.